Developments in the pharmacology and therapeutics of parkinsonism
Identifieur interne : 002C30 ( Main/Exploration ); précédent : 002C29; suivant : 002C31Developments in the pharmacology and therapeutics of parkinsonism
Auteurs : Calne [États-Unis]Source :
- Annals of Neurology [ 0364-5134 ] ; 1977-02.
Abstract
Advances in synaptic pharmacology have led to new approaches to understanding and attempting to alleviate the disturbances in neurotransmission that occur in parkinsonism. Techniques which were initially developed to elucidate normal synaptic phenomena are being employed to screen potential therapeutic agents for efficacy, relative potency, and neurotoxicity and to analyze the mechanism of action of antiparkinsonian drugs. In vitro methods utilizing striatal tissue include the assay of dopamine release, the determination of active dopamine reuptake, the displacement of ligands from dopamine receptors, and the stimulation of dopamine‐sensitive adenylate cyclase. In vivo test systems in rats comprise alleviation of the reserpine syndrome, induction of stereotypic behavior, measurement of turning after unilateral nigrostriatal lesions, evaluation of regional changes in the concentration of dopamine and its metabolites, and recording of single‐unit responses in the brain. With these tools, it is proving possible to sustain progress in the search for improved treatment, exemplified by current experimental studies with dopaminergic agonists and selective inhibitors of monoamine oxidase isoenzymes. The pursuit of practical applications has been accompanied by conceptual advances, such as the proposal that cyclic nucleotides are “second messengers” in the nigrostriatal pathway and the recognition of certain amino acids and peptides as synaptic transmitters or modulators in the basal ganglia.
Url:
DOI: 10.1002/ana.410010202
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Developments in the pharmacology and therapeutics of parkinsonism</title><author><name sortKey="Calne" sort="Calne" uniqKey="Calne" last="Calne">Calne</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EB4F877254872536ABCE7D9B89441D4FC7F7C0F9</idno><date when="1977" year="1977">1977</date><idno type="doi">10.1002/ana.410010202</idno><idno type="url">https://api.istex.fr/document/EB4F877254872536ABCE7D9B89441D4FC7F7C0F9/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002899</idno><idno type="wicri:Area/Main/Curation">002551</idno><idno type="wicri:Area/Main/Exploration">002C30</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Developments in the pharmacology and therapeutics of parkinsonism</title><author><name sortKey="Calne" sort="Calne" uniqKey="Calne" last="Calne">Calne</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1977-02">1977-02</date><biblScope unit="volume">1</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="111">111</biblScope><biblScope unit="page" to="119">119</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">EB4F877254872536ABCE7D9B89441D4FC7F7C0F9</idno><idno type="DOI">10.1002/ana.410010202</idno><idno type="ArticleID">ANA410010202</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Advances in synaptic pharmacology have led to new approaches to understanding and attempting to alleviate the disturbances in neurotransmission that occur in parkinsonism. Techniques which were initially developed to elucidate normal synaptic phenomena are being employed to screen potential therapeutic agents for efficacy, relative potency, and neurotoxicity and to analyze the mechanism of action of antiparkinsonian drugs. In vitro methods utilizing striatal tissue include the assay of dopamine release, the determination of active dopamine reuptake, the displacement of ligands from dopamine receptors, and the stimulation of dopamine‐sensitive adenylate cyclase. In vivo test systems in rats comprise alleviation of the reserpine syndrome, induction of stereotypic behavior, measurement of turning after unilateral nigrostriatal lesions, evaluation of regional changes in the concentration of dopamine and its metabolites, and recording of single‐unit responses in the brain. With these tools, it is proving possible to sustain progress in the search for improved treatment, exemplified by current experimental studies with dopaminergic agonists and selective inhibitors of monoamine oxidase isoenzymes. The pursuit of practical applications has been accompanied by conceptual advances, such as the proposal that cyclic nucleotides are “second messengers” in the nigrostriatal pathway and the recognition of certain amino acids and peptides as synaptic transmitters or modulators in the basal ganglia.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Calne" sort="Calne" uniqKey="Calne" last="Calne">Calne</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C30 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C30 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:EB4F877254872536ABCE7D9B89441D4FC7F7C0F9
|texte= Developments in the pharmacology and therapeutics of parkinsonism
}}
| This area was generated with Dilib version V0.6.23. |  |